Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-011 in advanced solid tumors
NCT04687423Phase 1Unknown
- Sponsor
- Fochon Biosciences
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FCN-011 in solid tumor, sponsored by Fochon Biosciences. Primary endpoints: Dose Limiting Toxicities at 30 days, Recommended Phase II Dose and 1 more. Status: unknown.
02
Drugs
FCN-011
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04687423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687423.